BB Biotech AG reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was CHF 0.27 million compared to CHF 0.649 million a year ago. Net income was CHF 260.49 million compared to net loss of CHF 253.86 million a year ago.

Basic earnings per share from continuing operations was CHF 4.75 compared to basic loss per share from continuing operations of CHF 4.63 a year ago. Diluted earnings per share from continuing operations was CHF 4.75 compared to diluted loss per share from continuing operations of CHF 4.63 a year ago.